Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Profit After Tax (2022 - 2025)

Stoke Therapeutics has reported Profit After Tax over the past 4 years, most recently at -$57.9 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$57.9 million for Q4 2025, down 452.7% from a year ago — trailing twelve months through Dec 2025 was -$6.9 million (up 92.26% YoY), and the annual figure for FY2025 was -$6.9 million, up 92.26%.
  • Profit After Tax for Q4 2025 was -$57.9 million at Stoke Therapeutics, down from -$38.3 million in the prior quarter.
  • Over the last five years, Profit After Tax for STOK hit a ceiling of $112.9 million in Q1 2025 and a floor of -$57.9 million in Q4 2025.
  • Median Profit After Tax over the past 4 years was -$25.7 million (2022), compared with a mean of -$18.9 million.
  • Peak annual rise in Profit After Tax hit 527.99% in 2025, while the deepest fall reached 452.7% in 2025.
  • Stoke Therapeutics' Profit After Tax stood at -$25.7 million in 2022, then dropped by 5.08% to -$27.0 million in 2023, then skyrocketed by 61.12% to -$10.5 million in 2024, then tumbled by 452.7% to -$57.9 million in 2025.
  • The last three reported values for Profit After Tax were -$57.9 million (Q4 2025), -$38.3 million (Q3 2025), and -$23.5 million (Q2 2025) per Business Quant data.